Original language | English |
---|---|
Pages (from-to) | 1339-1340 |
Number of pages | 2 |
Journal | Intensive Care Medicine |
Volume | 47 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Intensive Care Medicine, Vol. 47, No. 11, 11.2021, p. 1339-1340.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - COVID-19 associated pulmonary aspergillosis
T2 - regional variation in incidence and diagnostic challenges
AU - on behalf of the ECMM-CAPA Study Group
AU - Prattes, Juergen
AU - Koehler, Philipp
AU - Hoenigl, Martin
AU - Wauters, Joost
AU - Giacobbe, Daniele Roberto
AU - Lagrou, Katrien
AU - Salmanton-García, Jon
AU - Rautemaa-Richardson, Riina
AU - Hatzl, Stefan
AU - Maertens, Johan
AU - Debaveye, Yves
AU - Bourgeois, Marc
AU - Reynders, Marijke
AU - Rutsaert, Lynn
AU - Van Regenmortel, Niels
AU - Lormans, Piet
AU - Feys, Simon
AU - Reisinger, Alexander Christian
AU - Cornely, Oliver A.
AU - Lahmer, Tobias
AU - Valerio, Maricela
AU - Delhaes, Laurence
AU - Jabeen, Kauser
AU - Steinmann, Joerg
AU - Chamula, Mathilde
AU - Bassetti, Matteo
N1 - Funding Information: JP has received personal fees from Gilead Sciences and Pfizer, research funding from MSD and is stoke holder of AbbVie Inc and Novo Nordisk. PK is supported by the German Federal Ministry of Research and Education and the State of North Rhine-Westphalia, Germany and has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany, and received lecture honoraria from and/or is advisor to Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, Noxxon N.V., and University Hospital, LMU Munich outside the submitted work. MH received research funding from Gilead Sciences, Astellas, Scynexis, F2G and Pfizer. Funding Information: ECMM Study Group Authors: Joost Wauters, Daniele Roberto Giacobbe, Katrien Lagrou, Jon Salmanton-García, Riina Rautemaa-Richardson, Stefan Hatzl, Johan Maertens, Yves Debaveye, Marc Bourgeois, Marijke Reynders, Lynn Rutsaert, Niels Van Regenmortel, Piet Lormans, Simon Feys, Alexander Christian Reisinger, Oliver A. Cornely, Tobias Lahmer, Maricela Valerio, Laurence Delhaes, Kauser Jabeen, Joerg Steinmann, Mathilde Chamula, Matteo Bassetti.
PY - 2021/11
Y1 - 2021/11
UR - http://www.scopus.com/inward/record.url?scp=85114367473&partnerID=8YFLogxK
U2 - 10.1007/s00134-021-06510-2
DO - 10.1007/s00134-021-06510-2
M3 - Letter
C2 - 34468820
AN - SCOPUS:85114367473
SN - 0342-4642
VL - 47
SP - 1339
EP - 1340
JO - Intensive Care Medicine
JF - Intensive Care Medicine
IS - 11
ER -